← All trials
NCT02938975
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2017
- Primary completion
- Jan 31, 2019
- Completion date
- Jun 30, 2019
- First posted
- Oct 19, 2016
- Last posted
- Jun 6, 2017
- Enrollment
- 1500
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ifakara Health InstituteLead sponsor
- Ifakara Health InstituteOverall official - principal investigator
- University of BaselCollaborator
- United States ArmyCollaborator
- United States ArmyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.